# Aehr Test Systems: financial statements, quarterly

AEHR · Nasdaq · CIK 1040470 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/aehr.md) · [Financials](/companies/aehr/financials.md) · [Filings](/companies/aehr/filings.md) · [Insiders](/companies/aehr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/aehr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-08-30) | Q2 FY2024 (2023-11-30) | Q3 FY2024 (2024-02-29) | Q4 FY2024 (2024-05-31) | Q1 FY2025 (2024-08-30) | Q2 FY2025 (2024-11-29) | Q3 FY2025 (2025-02-28) | Q4 FY2025 (2025-05-30) | Q1 FY2026 (2025-08-29) | Q2 FY2026 (2025-11-28) | Q3 FY2026 (2026-02-27) | Q4 FY2026 (2026-05-29) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [20.6](/filings/0001654954-24-012913.md) | [21.4](/filings/0001654954-25-000285.md) | [7.6](/filings/0001654954-25-004120.md) | [16.6 d](/filings/0001654954-26-006919.md) | [13.1](/filings/0001654954-25-011582.md) | [13.5](/filings/0001654954-26-000266.md) | [18.3](/filings/0001654954-26-003348.md) | [14.1 d](/filings/0001654954-26-006919.md) | [11.0](/filings/0001654954-25-011582.md) | [9.9](/filings/0001654954-26-000266.md) | [10.3](/filings/0001654954-26-003348.md) | [18.8 d](/filings/0001654954-26-006919.md) |
| Cost of revenue | $m | [10.6](/filings/0001654954-24-012913.md) | [10.5](/filings/0001654954-25-000285.md) | [4.4](/filings/0001654954-25-004120.md) | [8.2 d](/filings/0001654954-26-006919.md) | [6.0](/filings/0001654954-25-011582.md) | [8.1](/filings/0001654954-26-000266.md) | [11.1](/filings/0001654954-26-003348.md) | [9.8 d](/filings/0001654954-26-006919.md) | [7.3](/filings/0001654954-25-011582.md) | [7.3](/filings/0001654954-26-000266.md) | [6.9](/filings/0001654954-26-003348.md) | [10.8 d](/filings/0001654954-26-006919.md) |
| Gross profit | $m | [10.0](/filings/0001654954-24-012913.md) | [11.0](/filings/0001654954-25-000285.md) | [3.2](/filings/0001654954-25-004120.md) | [8.4 d](/filings/0001654954-26-006919.md) | [7.1](/filings/0001654954-25-011582.md) | [5.4](/filings/0001654954-26-000266.md) | [7.2](/filings/0001654954-26-003348.md) | [4.3 d](/filings/0001654954-26-006919.md) | [3.7](/filings/0001654954-25-011582.md) | [2.5](/filings/0001654954-26-000266.md) | [3.4](/filings/0001654954-26-003348.md) | [8.0 d](/filings/0001654954-26-006919.md) |
| Research and development | $m | [2.5](/filings/0001654954-24-012913.md) | [2.0](/filings/0001654954-25-000285.md) | [2.1](/filings/0001654954-25-004120.md) | [2.2 d](/filings/0001654954-26-006919.md) | [2.4](/filings/0001654954-25-011582.md) | [2.3](/filings/0001654954-26-000266.md) | [3.1](/filings/0001654954-26-003348.md) | [2.7 d](/filings/0001654954-26-006919.md) | [2.8](/filings/0001654954-25-011582.md) | [3.0](/filings/0001654954-26-000266.md) | [3.2](/filings/0001654954-26-003348.md) | [3.6 d](/filings/0001654954-26-006919.md) |
| Selling, general and administrative | $m | [3.4](/filings/0001654954-24-012913.md) | [3.5](/filings/0001654954-25-000285.md) | [3.1](/filings/0001654954-25-004120.md) | [3.8 d](/filings/0001654954-26-006919.md) | [4.6](/filings/0001654954-25-011582.md) | [4.6](/filings/0001654954-26-000266.md) | [5.2](/filings/0001654954-26-003348.md) | [3.9 d](/filings/0001654954-26-006919.md) | [4.7](/filings/0001654954-25-011582.md) | [4.4](/filings/0001654954-26-000266.md) | [4.4](/filings/0001654954-26-003348.md) | [5.6 d](/filings/0001654954-26-006919.md) |
| Operating income | $m | [4.1](/filings/0001654954-24-012913.md) | [5.5](/filings/0001654954-25-000285.md) | [(2.0)](/filings/0001654954-25-004120.md) | [2.5 d](/filings/0001654954-26-006919.md) | [0.2](/filings/0001654954-25-011582.md) | [(1.5)](/filings/0001654954-26-000266.md) | [(1.1)](/filings/0001654954-26-003348.md) | [(3.2) d](/filings/0001654954-26-006919.md) | [(4.1)](/filings/0001654954-25-011582.md) | [(4.6)](/filings/0001654954-26-000266.md) | [(4.2)](/filings/0001654954-26-003348.md) | [(1.2) d](/filings/0001654954-26-006919.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0001654954-24-012913.md) | [0.0](/filings/0001654954-25-000285.md) | [0.0](/filings/0001654954-25-004120.md) | [(20.7) d](/filings/0001654954-26-006919.md) | [0.2](/filings/0001654954-25-011582.md) | [(0.2)](/filings/0001654954-26-000266.md) | [(0.2)](/filings/0001654954-26-003348.md) | [(0.1) d](/filings/0001654954-26-006919.md) | [(0.8)](/filings/0001654954-25-011582.md) | [(1.2)](/filings/0001654954-26-000266.md) | [(0.8)](/filings/0001654954-26-003348.md) | [(1.8) d](/filings/0001654954-26-006919.md) |
| Net income | $m | [4.7](/filings/0001654954-24-012913.md) | [6.1](/filings/0001654954-25-000285.md) | [(1.5)](/filings/0001654954-25-004120.md) | [23.9 d](/filings/0001654954-26-006919.md) | [0.7](/filings/0001654954-25-011582.md) | [(1.0)](/filings/0001654954-26-000266.md) | [(0.6)](/filings/0001654954-26-003348.md) | [(2.9) d](/filings/0001654954-26-006919.md) | [(2.1)](/filings/0001654954-25-011582.md) | [(3.2)](/filings/0001654954-26-000266.md) | [(3.2)](/filings/0001654954-26-003348.md) | [1.4 d](/filings/0001654954-26-006919.md) |
| Diluted EPS | $ per share | [0.16](/filings/0001654954-24-012913.md) | [0.20](/filings/0001654954-25-000285.md) | [(0.05)](/filings/0001654954-25-004120.md) | not reported | [0.02](/filings/0001654954-25-011582.md) | [(0.03)](/filings/0001654954-26-000266.md) | [(0.02)](/filings/0001654954-26-003348.md) | not reported | [(0.07)](/filings/0001654954-25-011582.md) | [(0.11)](/filings/0001654954-26-000266.md) | [(0.10)](/filings/0001654954-26-003348.md) | not reported |
| Basic EPS | $ per share | [0.16](/filings/0001654954-24-012913.md) | [0.21](/filings/0001654954-25-000285.md) | [(0.05)](/filings/0001654954-25-004120.md) | not reported | [0.02](/filings/0001654954-25-011582.md) | [(0.03)](/filings/0001654954-26-000266.md) | [(0.02)](/filings/0001654954-26-003348.md) | not reported | [(0.07)](/filings/0001654954-25-011582.md) | [(0.11)](/filings/0001654954-26-000266.md) | [(0.10)](/filings/0001654954-26-003348.md) | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2023-08-31) | Q2 FY2024 (2023-11-30) | Q3 FY2024 (2024-02-29) | FY2024 (2024-05-31) | Q1 FY2025 (2024-08-30) | Q2 FY2025 (2024-11-29) | Q3 FY2025 (2025-02-28) | FY2025 (2025-05-30) | Q1 FY2026 (2025-08-29) | Q2 FY2026 (2025-11-28) | Q3 FY2026 (2026-02-27) | FY2026 (2026-05-29) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [51.0](/filings/0001654954-23-012844.md) | [50.5](/filings/0001654954-24-000525.md) | [47.6](/filings/0001654954-24-004455.md) | [49.2](/filings/0001654954-25-008553.md) | [37.8](/filings/0001654954-24-012913.md) | [32.2](/filings/0001654954-25-000285.md) | [29.4](/filings/0001654954-25-004120.md) | [24.5](/filings/0001654954-26-006919.md) | [22.7](/filings/0001654954-25-011582.md) | [30.8](/filings/0001654954-26-000266.md) | [36.9](/filings/0001654954-26-003348.md) | [116](/filings/0001654954-26-006919.md) |
| Current assets | $m | [96.2](/filings/0001654954-23-012844.md) | [91.8](/filings/0001654954-24-000525.md) | [92.3](/filings/0001654954-24-004455.md) | [97.8](/filings/0001654954-25-008553.md) | [92.9](/filings/0001654954-24-012913.md) | [88.5](/filings/0001654954-25-000285.md) | [91.7](/filings/0001654954-25-004120.md) | [88.8](/filings/0001654954-26-006919.md) | [84.1](/filings/0001654954-25-011582.md) | [88.2](/filings/0001654954-26-000266.md) | [95.9](/filings/0001654954-26-003348.md) | [184](/filings/0001654954-26-006919.md) |
| Total assets | $m | [105](/filings/0001654954-23-012844.md) | [101](/filings/0001654954-24-000525.md) | [102](/filings/0001654954-24-004455.md) | [128](/filings/0001654954-25-008553.md) | [146](/filings/0001654954-24-012913.md) | [142](/filings/0001654954-25-000285.md) | [146](/filings/0001654954-25-004120.md) | [149](/filings/0001654954-26-006919.md) | [144](/filings/0001654954-25-011582.md) | [149](/filings/0001654954-26-000266.md) | [157](/filings/0001654954-26-003348.md) | [247](/filings/0001654954-26-006919.md) |
| Current liabilities | $m | [19.3](/filings/0001654954-23-012844.md) | [8.0](/filings/0001654954-24-000525.md) | [9.2](/filings/0001654954-24-004455.md) | [10.5](/filings/0001654954-25-008553.md) | [15.4](/filings/0001654954-24-012913.md) | [11.7](/filings/0001654954-25-000285.md) | [16.1](/filings/0001654954-25-004120.md) | [15.6](/filings/0001654954-26-006919.md) | [11.9](/filings/0001654954-25-011582.md) | [8.3](/filings/0001654954-26-000266.md) | [8.7](/filings/0001654954-26-003348.md) | [17.9](/filings/0001654954-26-006919.md) |
| Total liabilities | $m | [25.3](/filings/0001654954-23-012844.md) | [14.0](/filings/0001654954-24-000525.md) | [15.1](/filings/0001654954-24-004455.md) | [16.3](/filings/0001654954-25-008553.md) | [23.4](/filings/0001654954-24-012913.md) | [19.1](/filings/0001654954-25-000285.md) | [21.4](/filings/0001654954-25-004120.md) | [25.6](/filings/0001654954-26-006919.md) | [21.7](/filings/0001654954-25-011582.md) | [18.0](/filings/0001654954-26-000266.md) | [18.3](/filings/0001654954-26-003348.md) | [27.2](/filings/0001654954-26-006919.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [80.1](/filings/0001654954-25-000285.md) | [87.2](/filings/0001654954-25-004120.md) | [86.5](/filings/0001654954-25-004120.md) | [112](/filings/0001654954-26-006919.md) | [122](/filings/0001654954-26-000266.md) | [123](/filings/0001654954-26-003348.md) | [124](/filings/0001654954-26-003348.md) | [123](/filings/0001654954-26-006919.md) | [122](/filings/0001654954-26-000266.md) | [131](/filings/0001654954-26-003348.md) | [139](/filings/0001654954-26-003348.md) | [220](/filings/0001654954-26-006919.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-08-31) | Q2 FY2024 (2023-11-30) | Q3 FY2024 (2024-02-29) | Q4 FY2024 (2024-05-31) | Q1 FY2025 (2024-08-30) | Q2 FY2025 (2024-11-29) | Q3 FY2025 (2025-02-28) | Q4 FY2025 (2025-05-30) | Q1 FY2026 (2025-08-29) | Q2 FY2026 (2025-11-28) | Q3 FY2026 (2026-02-27) | Q4 FY2026 (2026-05-29) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [3,901](/filings/0001654954-24-012913.md) | [(545) d](/filings/0001654954-25-000285.md) | [(2,824) d](/filings/0001654954-25-004120.md) | [1,224 d](/filings/0001654954-26-006919.md) | [2,380](/filings/0001654954-25-011582.md) | [(5,873) d](/filings/0001654954-26-000266.md) | [(1,605) d](/filings/0001654954-26-003348.md) | [(2,302) d](/filings/0001654954-26-006919.md) | [(282)](/filings/0001654954-25-011582.md) | [(1,171) d](/filings/0001654954-26-000266.md) | [(3,689) d](/filings/0001654954-26-003348.md) | [1,832 d](/filings/0001654954-26-006919.md) |
| Capital expenditure | $k | [284](/filings/0001654954-24-012913.md) | [156 d](/filings/0001654954-25-000285.md) | [263 d](/filings/0001654954-25-004120.md) | [46.0 d](/filings/0001654954-26-006919.md) | [197](/filings/0001654954-25-011582.md) | [321 d](/filings/0001654954-26-000266.md) | [1,656 d](/filings/0001654954-26-003348.md) | [2,818 d](/filings/0001654954-26-006919.md) | [1,391](/filings/0001654954-25-011582.md) | [467 d](/filings/0001654954-26-000266.md) | [74.0 d](/filings/0001654954-26-003348.md) | [134 d](/filings/0001654954-26-006919.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2022-08-31) | Q2 FY2023 (2022-11-30) | Q3 FY2023 (2023-02-28) | Q1 FY2024 (2023-08-31) | Q2 FY2024 (2023-11-30) | Q3 FY2024 (2024-02-29) | Q1 FY2025 (2024-08-30) | Q2 FY2025 (2024-11-29) | Q3 FY2025 (2025-02-28) | Q1 FY2026 (2025-08-29) | Q2 FY2026 (2025-11-28) | Q3 FY2026 (2026-02-27) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [28.8](/filings/0001654954-23-012844.md) | [0.0](/filings/0001654954-24-000525.md) | [29.4](/filings/0001654954-24-004455.md) | [29.6](/filings/0001654954-24-012913.md) | [29.8](/filings/0001654954-25-000285.md) | [28.9](/filings/0001654954-25-004120.md) | [29.6](/filings/0001654954-25-011582.md) | [29.7](/filings/0001654954-26-000266.md) | [29.7](/filings/0001654954-26-003348.md) | [29.9](/filings/0001654954-25-011582.md) | [30.2](/filings/0001654954-26-000266.md) | [30.7](/filings/0001654954-26-003348.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 32,620,450 at 2026-07-20, from the cover of the [10-K filed 2026-07-27](/filings/0001654954-26-006919.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:31 ET. No prices; not investment advice.